OncoKB Therapeutic Levels of Evidence

FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication

Standard care biomarker predictive of response to an FDA-approved drug in this indication*

Standard care biomarker predictive of response to an **FDA-approved** drug **in another indication**, but not standard care in this indication

Compelling clinical evidence supports the biomarker as being predictive of response to a drug **in this indication**

Compelling clinical evidence supports the biomarker as being predictive of response to a drug **in another indication**

Compelling biological evidence supports the biomarker as being predictive of response to a drug

Standard care biomarker predictive of **resistance** to an **FDA-approved** drug **in this indication**

Compelling clinical evidence supports the biomarker as being predictive of **resistance** to a drug

Standard Therapeutic Implications

*Includes biomarkers that are recommended as standard care by the NCCN or other expert panels but not necessarily FDArecognized for a particular indication

Investigational Therapeutic Implications

possibly directed to clinical trials

Hypothetical Therapeutic Implications based on preliminary, non-clinical data

Standard Resistance Implications

Investigational Resistance Implications

based on clinical data

R1

2B

3A

3B

4

R2